BioXcel Therapeutics (BTAI) Reports Q2 Loss of $1.06/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. FIS
3. ARM
4. BROS
5. QCOM
6. EXPE
7. FSLY
8. CPAY
9. FICO
10. PAYC

Go back to BioXcel Therapeutics (BTAI) Reports Q2 Loss of $1.06/sh

BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

August 14, 2020 7:00 AM EDT

SERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application (NDA) submission to U.S. Food and Drug Administration (FDA) planned for Q1 2021

Initiating the third dose cohort, 90 mcg, of the TRANQUILITY trial in elderly dementia patients

Initiated a separate efficacy cohort in the Phase 2 trial of BXCL701 in combination with pembrolizumab (KEYTRUDA®) to include patients with castrate-resistant prostate cancer (CRPC)

Strengthened balance sheet through follow-on offering raising approximately $200 million in gross proceeds

Company... More